全文获取类型
收费全文 | 26793篇 |
免费 | 2169篇 |
国内免费 | 653篇 |
专业分类
耳鼻咽喉 | 136篇 |
儿科学 | 740篇 |
妇产科学 | 613篇 |
基础医学 | 1061篇 |
口腔科学 | 254篇 |
临床医学 | 2800篇 |
内科学 | 5306篇 |
皮肤病学 | 239篇 |
神经病学 | 1655篇 |
特种医学 | 418篇 |
外科学 | 2858篇 |
综合类 | 3725篇 |
预防医学 | 6050篇 |
眼科学 | 200篇 |
药学 | 2362篇 |
13篇 | |
中国医学 | 137篇 |
肿瘤学 | 1048篇 |
出版年
2024年 | 41篇 |
2023年 | 555篇 |
2022年 | 1255篇 |
2021年 | 1460篇 |
2020年 | 1371篇 |
2019年 | 1062篇 |
2018年 | 1118篇 |
2017年 | 1093篇 |
2016年 | 1258篇 |
2015年 | 1132篇 |
2014年 | 2598篇 |
2013年 | 2363篇 |
2012年 | 2024篇 |
2011年 | 2184篇 |
2010年 | 1544篇 |
2009年 | 1345篇 |
2008年 | 1275篇 |
2007年 | 1200篇 |
2006年 | 970篇 |
2005年 | 785篇 |
2004年 | 566篇 |
2003年 | 447篇 |
2002年 | 357篇 |
2001年 | 327篇 |
2000年 | 268篇 |
1999年 | 164篇 |
1998年 | 116篇 |
1997年 | 138篇 |
1996年 | 92篇 |
1995年 | 88篇 |
1994年 | 75篇 |
1993年 | 62篇 |
1992年 | 60篇 |
1991年 | 53篇 |
1990年 | 39篇 |
1989年 | 27篇 |
1988年 | 30篇 |
1987年 | 17篇 |
1986年 | 8篇 |
1985年 | 12篇 |
1984年 | 10篇 |
1983年 | 6篇 |
1982年 | 6篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1977年 | 4篇 |
1976年 | 1篇 |
1906年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
目的 为给兽药减量政策的制定、动物源性食品安全的维护提供理论依据。方法 利用每日允许摄入量(ADI)、估算每日摄入量(EDI)及慢性风险熵(CRQ),对中国居民通过摄入肉蛋乳等动物性食品暴露于吉他霉素的耐药性风险进行点评估。结果 随着年龄增长,中国居民的吉他霉素膳食暴露量逐渐降低。2~7岁人群吉他霉素的膳食暴露量最高,男女分别为2.17和2.29 μg/ ( kg·bw·d);>65岁人群膳食暴露量最低,男女分别为0.45和0.46 μg/ ( kg·bw·d)。2~7岁人群通过摄入乳制品的吉他霉素的膳食暴露量最大,男女分别为1.15和1.22 μg/ ( kg·bw·d),8岁以上人群通过摄入肉类食品的吉他霉素的膳食暴露量最大。中国居民通过摄入肉蛋乳等动物性食品暴露于吉他霉素,各年龄段CRQ均小于1。其中2~7岁人群CRQ值最高,风险最大;65岁以上人群CRQ值最低,风险最小。结论 中国居民通过摄入动物性食品的吉他霉素耐药性风险较低,危害程度较小,但儿童通过摄入乳制品的吉他霉素耐药性风险较高,有必要制定乳制品中吉他霉素残留的限量标准。 相似文献
4.
5.
6.
Stones in the common bile duct (CBD) are reported worldwide, and this condition is majorly managed through endoscopic retrograde cholangiopancreatography (ERCP). CBD stone recurrence is an important issue after endoscopic stone removal. Therefore, it is essential to identify its risk factors to determine the necessity of regular follow-up in patients who underwent endoscopic removal of CBD stones. The authors identified that the S and polyline morphological subtypes of CBD were associated with increased stone recurrence. New morphological subtypes of CBD presented by the authors can be important risk predictors of recurrence after endoscopic stone removal. Furthermore, the new morphological subtypes of CBD may predict the risk of residual CBD stones or technical difficulty in CBD stone removal. Further studies with a large sample size and longer follow-up durations are warranted to examine the usefulness of the newly identified morphological subtypes of CBD in predicting the outcomes of ERCP for CBD stone removal. 相似文献
7.
《Journal of infection and chemotherapy》2022,28(2):339-342
This study aimed to clarify the characteristics of patients with lung cancer undergoing treatment until the onset of tuberculosis. Between 2005 and 2019, patients who were admitted to Tokyo National Hospital due to tuberculosis during lung cancer treatment were examined retrospectively. There were 42 patients, and detailed medical information was obtained in 39 patients. The median age of the 39 patients were 75 years (range: 47–92 years), of which 33 were males and 36 were Japanese Baby Boomers or older. Regarding risk factors for developing tuberculosis, smoking was noted in 34 cases, oral corticosteroid use in 13, and previous tuberculosis in six. Thirty-seven patients had one risk factor and 19 had two or more risk factors, but diagnosis of latent tuberculosis infection (LTBI) was obtained in only one patients, and none had received LTBI treatment. The first-line treatment for lung cancer was resection in 13 cases, chemoradiotherapy in 6, chemotherapy in 10, radiation therapy in 3, laser therapy in 1, and best supportive care (BSC) alone in 6. At tuberculosis onset, BSC accounted for 17 cases, but other situations were considerably existed such as anticancer medication (12 cases), and observation after lung cancer treatment (10 cases). Tuberculosis occurred in various situations in elderly patients with lung cancer. It is critical to actively evaluate the risk of tuberculosis and consider LTBI screening and treatment. 相似文献
8.
《Taiwanese journal of obstetrics & gynecology》2022,61(1):80-85
ObjectiveTo investigate the risk of occurrence of second primary malignancies (SPMs) in survivors of ovarian cancer (OC) using large data from the Surveillance, Epidemiology, and End Results (SEER) database.Materials and methodsMultiple primaries standardized incidence ratios (MP-SIRs) to calculate the risk of developing second primary malignancies after a diagnosis of ovarian cancer.ResultsOf our included 59,880 women with OC, 3972 cases (6.6%) developed 4495 s primary malignancies over an average follow-up period of 114.39 (±102.66) months. Overall, the risk of occurrence of second primary malignancies after a diagnosis of OC was greater than what would be expected for a reference US population (SIR = 1.05, 95%CI = 1.02–1.08, p-value < 0.05). The occurrence of second myeloid malignancies and second thyroid cancer were most notable across our latency periods. Among the most significant second primary malignancies by latency were malignancies of the appendix (SIR = 14.04, 95%CI = 5.65–28.93, p-value <0.05) at 2–11 months, the small intestine (SIR = 3.15, 95%CI = 1.76–5.2, p-value <0.05) at 12–59 months, and the urinary bladder (SIR = 1.63, 95%CI = 1.3–2.02, p-value <0.05) after 10 years of an OC diagnosis.ConclusionWomen with OC are at significant risk for the development of second primary malignancies across all sites, as compared to a reference US population, and may benefit from second primary malignancies site-specific screening post-diagnosis. 相似文献
9.
10.
《Drug discovery today》2022,27(10):103321
Pain is a constant in our lives. The efficacy of drug therapy administered by the parenteral route is often limited either by the physicochemical characteristics of the drug itself or its adsorption–distribution–metabolism–excretion (ADME) mechanisms. One promising alternative is the design of innovative drug delivery systems that can improve the pharmacokinetics |(PK) and/or reduce the toxicity of traditionally used drugs. In this review, we discuss several products that have been approved by the main regulatory agencies (i.e., nano- and microsystems, implants, and oil-based solutions), highlighting the newest technologies that govern both locally and systemically the delivery of drugs. Finally, we also discuss the risk assessment of the scale-up process required, given the impact that this approach could have on drug manufacturing.Teaser: The management of pain by way of the parenteral route can be improved using complex drug delivery systems (e.g., micro- and nanosystems) which require high-level assessment and shorten the regulatory pathway. 相似文献